The Craig H. Neilsen Foundation   Report issue

Foundation Phase 2 Phase 4
Founded: Encino CA United States (2002)

Organization Overview

First Clinical Trial
2006
NCT00320281
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

The Craig H. Neilsen Foundation

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cognitive Dysfunction (Phase 4)

Hypothermia (Phase 4)

Metabolic Syndrome (Phase 2)

Osteoporosis (Phase 2)

Quadriplegia (Phase 4)

Shoulder Pain (Phase 4)

Spinal Cord Injuries (Phase 4)

Wounds and Injuries (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 7